辉瑞寻求出售在BioNTech的全部剩余股权

Core Viewpoint - Pfizer is seeking to sell its remaining stake in COVID-19 vaccine partner BioNTech through a block trade of approximately 4.55 million American Depositary Receipts (ADRs) priced between $108 and $111.70 per share, potentially generating around $508 million in revenue at the upper price range [1] Group 1 - Pfizer plans to sell about 4.55 million ADRs of BioNTech [1] - The pricing range for the sale is set between $108 and $111.70 per share [1] - If priced at the upper limit, the sale could yield approximately $508 million for Pfizer [1]